About Nucleus Laboratories (India) Limted
Data last updated:
Nucleus Laboratories (India) Limted is a public limited company based in Lucknow, Uttar Pradesh, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 07 December 1999 and has been in existence for over 27 years.
The company is registered with the Registrar of Companies (ROC), Kanpur, under CIN U24231UP1999PLC024944. Its GSTIN is 09AABCN9670P1ZL (Uttar Pradesh). The company holds 2 GST registrations, of which 1 is active.
The company has an authorised share capital of ₹1 Cr and a paid-up capital of ₹1 Cr. It is led by directors including Ashish Kumar Singh and Gyan Prakash Shrivastava.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Lucknow, Uttar Pradesh.
As per the financials filed for FY 2020, the company reported a revenue of ₹2.48 Cr, a decline of 16% compared to the previous year. For the same year it recorded a net loss of ₹18.46 Lakh (net margin -7.4%) and EBITDA of -₹23.78 Lakh (EBITDA margin -9.6%). Revenue has grown at a compounded annual rate (CAGR) of 140% over three years and 57% over five years.
The company is associated with 1 brand: Nucleus Laboratories. As per MCA filings, the company has open charges of ₹30 Lakh on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website nucleuslaboratories.com.
Company details
Contact details
Nucleus Laboratories (India) Limted's registered office is in Lucknow, Uttar Pradesh. Its website is nucleuslaboratories.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered AddressFlat No. 101 First Floor, Omaxe Avenue Omaxe City, Lucknow, Uttar Pradesh, India – 226025
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Nucleus Laboratories (India) Limted, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Nucleus Laboratories (India) Limted operates one associated brand: Nucleus Laboratories. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Provides comprehensive quality management solutions for the biopharma sector. | nucleuslaboratories.com |
Financials of Nucleus Laboratories (India) Limted
FY 2025 filings availableNucleus Laboratories (India) Limted reported revenue of ₹2.48 Cr (down 16% YoY) for FY 2020.
Compounded Annual Growth Rate (CAGR)
Revenue fell 16% in the latest year, but over five years it has grown at a compounded annual rate (CAGR) of 57%. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2019-20 | FY 2018-19 | FY 2017-18 | FY 2016-17 | FY 2015-16 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | ₹2.48 Cr | ||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | -₹23.78 Lakh | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | -₹18.46 Lakh | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2019-20 | FY 2018-19 | FY 2017-18 | FY 2016-17 | FY 2015-16 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | -9.6% | ||||
| Net Profit Margin | -7.4% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Nucleus Laboratories (India) Limted, buy the company report.
Board of directors of Nucleus Laboratories (India) Limted
Nucleus Laboratories (India) Limted has 5 current directors and 6 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Ashish Kumar Singh | Director | 27 Nov 2000 | 25 Years 11 Months | Current |
| Gyan Prakash Shrivastava | Director | 07 Mar 2022 | 4 Years 7 Months | Current |
| Chandana Shrivastava Also directs: Global Drugs and Vaccines Private Limited | Director | 07 Mar 2022 | 4 Years 7 Months | Current |
| Himani Shukla | Director | 01 Aug 2025 | 1 Years 2 Months | Current |
| Debashish Saha | Director | 01 Jun 2023 | 3 Years 4 Months | Current |
Auditor
Nucleus Laboratories (India) Limted is audited by AJAI SHANKER & CO for the financial year 2020.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| AJAI SHANKER & CO | FY 2020 | 002707C |
Shareholding
The shareholding of Nucleus Laboratories (India) Limted is on record for 5 financial years, the latest being FY 2020, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Nucleus Laboratories (India) Limted, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 02 Jun 2018 | 100184214 | Bank of India | ₹30 Lakh | Open |
Total charge records: 1 View all charges
Legal cases
No court or tribunal cases involving Nucleus Laboratories (India) Limted are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Nucleus Laboratories (India) Limted; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Nucleus Laboratories (India) Limted has 2 GST registrations: 1 active and 1 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 09AABCN9670P1ZL | Uttar Pradesh | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Nucleus Laboratories (India) Limted, buy the company report.
Recent activity
Nucleus Laboratories (India) Limted has 17 board changes on record since 1999: 11 appointments and 6 cessations. The latest: Himani Shukla was appointed as Director on 01 Aug 2025.
9 earlier events are in the company report.
Frequently asked questions
Nucleus Laboratories (India) Limted is an active public limited company based in Lucknow, Uttar Pradesh, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 07 December 1999 (27+ years old) and is registered under CIN U24231UP1999PLC024944.
Nucleus Laboratories (India) Limted has 5 current directors:
- Ashish Kumar Singh - Director
- Gyan Prakash Shrivastava - Director
- Chandana Shrivastava - Director
- Himani Shukla - Director
- Debashish Saha - Director
The latest financial statements of Nucleus Laboratories (India) Limted on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Nucleus Laboratories (India) Limted is 09AABCN9670P1ZL, registered in Uttar Pradesh. The company has 2 GST registrations in all, of which 1 is active and 1 is cancelled or inactive.
The CIN (Corporate Identification Number) of Nucleus Laboratories (India) Limted is U24231UP1999PLC024944. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Nucleus Laboratories (India) Limted was incorporated on 07 December 1999, making it 27+ years old. It is registered with the Registrar of Companies, Kanpur.
Himani Shukla was appointed as Director on 01 Aug 2025. Avadhesh Pratap Singh ceased to be Additional Director on 01 Jun 2023. Debashish Saha was appointed as Director on 01 Jun 2023. Nucleus Laboratories (India) Limted has 17 board changes on record in total.
Nucleus Laboratories (India) Limted can be reached through the website nucleuslaboratories.com. Its registered office is in Lucknow, Uttar Pradesh, India.
The registered office of Nucleus Laboratories (India) Limted is at Flat No. 101 First Floor, Omaxe Avenue Omaxe City, Lucknow, Uttar Pradesh, India – 226025.
Nucleus Laboratories (India) Limted operates in the pharma industry, in the drug formulation and development segment.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
